Vandana Singh
·
March 31, 2025
Benzinga
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
read more
May 6, 2025
April 13, 2025
Bloomberg